|Summary of important one-and two way sensitivity analysesa|
|Interpretation of the incremental impact of the RS-assay compared to CCP|
|Variable (range tested)||Negative cost and effect||Cost savings||ICER in the range||ICER in the range||ICER in the range||Dominated|
|0 to 20,000 $/QALY gained||20,000 to 100,000 $/QALY gained||> 100,000 $/QALY gained|
|Chemotherapy treated women in intermediate risk group by the RS-assay (0% to 100%)||86% to 100%||42% to 85%||32% to 41%||0% to 31%|
|Change in absolute risk of relapseb in the RS-assay model (−10% to +10%)||< −3%||−3% to +0.9%||+1% to +2%||> +2%|
|Change in utility of recurrencec (−10% to +10%)||Lower limit cost of recurrencec||< +9%||≥ +9%|
|Baseline cost of recurrencec||−10% to +10%|
|Upper limit cost of recurrencec||−10% to +10%|
|Change in utility following adjuvant chemotherapy (−10% to +10%)||> 4.5%||−0.8% to +4.5%||−2.4% to −0.9%||≤ −2.5%|
CMF = 6 cycles of cyclophosphamide, methotrexate, 5-fluorouracil; AC = 4 cycles of adriamycin, cyclophosphamide; CCP = current clinical practice.
a Values in the table show how the incremental impact of the RS-assay compared to CCP changes, over 6 significant ranges, depending on the values of certain key parameters. For example, if between 42-85% of women identified as intermediate risk by the RS-assay were to receive chemotherapy, then the RS-assay has an ICER between $20,000 / QALY gained and $100,000 / QALY gained; if this proportion is between 32% and 41%, then the RS-assay has an ICER greater than $100,000 / QALY gained.
b Relapse includes loco-regional recurrence, distant recurrence and death due to any cause.
c Recurrence includes loco-regional and distant recurrences.
Hannouf et al.
Hannouf et al. BMC Cancer 2012 12:447 doi:10.1186/1471-2407-12-447